A study further supporting rVAR2 as a potentially universal cancer targeting molecule published in Nature Communications

Today our researchers at Copenhagen University and University of British Columbia together with academic partners in United Kingdom, Australia and Taiwan published an article in Nature Communications that demonstrates that rVAR2 indeed can be used as a tool to capture and isolate circulating tumour ......
Continue reading

VAR2 Pharmaceuticals featured in Medwatch.dk

Check out the article about VAR2 Pharmaceuticals and VarCT Diagnostics here.

Continue reading

VAR2 at the 2018 BIO International Convention

VAR2 will be represented by its COO, Andreas Linderoth Norlin, at this year's BIO International Convention taking place in Boston 4th to 7th June. We look forward to a great program and many exciting meetings with old and new partners in the biopharma business. See you there!

...
Continue reading

Professor Poul Sorensen presenting at AACR 2018

VAR2 Pharmaceuticals founder and member of the Board of Directors, Prof. Poul Sorensen, will give a talk with the title “Probing the surface proteome for immunotherapy targets in high-risk pediatric cancers” on Saturady April 14th at the AACR meeting in Chicago, IL. The presentation will highlight s......
Continue reading

VAR2 Pharmaceuticals to present new results at the AACR Annual meeting 2018

New significant data about chondroitin sulphate – the target for the VAR2 protein – in prostate cancer, will be presented on April 18th, at this year's AACR meeting in Chicago, IL. The work is presented in a poster entitled “Expression and regulation of chondroitin sulfate in prostate cancer” and is......
Continue reading